Detailed information for compound 149977

Basic information

Technical information
  • TDR Targets ID: 149977
  • Name: (2S)-2-[[(2S)-1-(3,5-dichlorophenyl)sulfonylp yrrolidine-2-carbonyl]amino]-3-(4-phenylpheny l)propanoic acid
  • MW: 547.45 | Formula: C26H24Cl2N2O5S
  • H donors: 2 H acceptors: 5 LogP: 5.41 Rotable bonds: 9
    Rule of 5 violations (Lipinski): 2
  • SMILES: OC(=O)[C@H](Cc1ccc(cc1)c1ccccc1)NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(c1)Cl
  • InChi: 1S/C26H24Cl2N2O5S/c27-20-14-21(28)16-22(15-20)36(34,35)30-12-4-7-24(30)25(31)29-23(26(32)33)13-17-8-10-19(11-9-17)18-5-2-1-3-6-18/h1-3,5-6,8-11,14-16,23-24H,4,7,12-13H2,(H,29,31)(H,32,33)/t23-,24-/m0/s1
  • InChiKey: BRZKFEHVZLVFIJ-ZEQRLZLVSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • (2S)-2-[[[(2S)-1-(3,5-dichlorophenyl)sulfonyl-2-pyrrolidinyl]-oxomethyl]amino]-3-(4-phenylphenyl)propanoic acid
  • (2S)-2-[[(2S)-1-(3,5-dichlorophenyl)sulfonylpyrrolidin-2-yl]carbonylamino]-3-(4-phenylphenyl)propanoic acid
  • (2S)-2-[[(2S)-1-(3,5-dichlorophenyl)sulfonylprolyl]amino]-3-(4-phenylphenyl)propionic acid
  • (2S)-2-[[(2S)-1-(3,5-dichlorophenyl)sulfonylpyrrolidine-2-carbonyl]amino]-3-(4-phenylphenyl)propionic acid

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Schistosoma japonicum Integrin beta-3 precursor, putative Get druggable targets OG5_127959 All targets in OG5_127959
Loa Loa (eye worm) integrin beta-2 Get druggable targets OG5_127959 All targets in OG5_127959
Echinococcus multilocularis integrin beta 2 Get druggable targets OG5_127959 All targets in OG5_127959
Schistosoma mansoni integrin beta subunit Get druggable targets OG5_127959 All targets in OG5_127959
Schistosoma japonicum ko:K06464 integrin beta 2, putative Get druggable targets OG5_127959 All targets in OG5_127959
Schistosoma japonicum Integrin beta-PS precursor, putative Get druggable targets OG5_127959 All targets in OG5_127959
Echinococcus granulosus integrin beta 2 Get druggable targets OG5_127959 All targets in OG5_127959
Brugia malayi Integrin beta pat-3 precursor Get druggable targets OG5_127959 All targets in OG5_127959
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Echinococcus multilocularis integrin beta 2 0.028 0.0088 0.5
Treponema pallidum licC protein (licC) 0.1154 0.1426 0.5
Toxoplasma gondii eukaryotic initiation factor-2B, gamma subunit, putative 0.1154 0.1426 0.5
Mycobacterium ulcerans bifunctional N-acetylglucosamine-1-phosphate uridyltransferase/glucosamine-1-phosphate acetyltransferase 0.675 1 1
Echinococcus granulosus integrin beta 2 0.028 0.0088 0.5
Loa Loa (eye worm) integrin beta-2 0.0378 0.0238 0.5
Schistosoma mansoni integrin beta subunit 0.0223 0 0.5
Brugia malayi Integrin beta pat-3 precursor 0.0378 0.0238 0.5
Wolbachia endosymbiont of Brugia malayi N-acetylglucosamine-1-phosphate uridyltransferase 0.675 1 0.5
Mycobacterium tuberculosis Probable UDP-N-acetylglucosamine pyrophosphorylase GlmU 0.675 1 1

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = -0.65 nM Inhibitory activity against very late antigen-4 (VLA-4) using VCAM-Ig ligand. ChEMBL. 11844689
IC50 (functional) = 0.63 nM Antagonistic activity against VLA-4 integrin of human jurkat cells using [125I]-VCAM-Ig as radioligand ChEMBL. 11591507
IC50 (functional) = 0.63 nM Antagonistic activity against VLA-4 integrin of human jurkat cells using [125I]-VCAM-Ig as radioligand ChEMBL. 11591507
IC50 (binding) = 0.65 nM Inhibitory activity against very late antigen-4 (VLA-4) using VCAM-Ig ligand. ChEMBL. 11844689

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

2 literature references were collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.